Table 2.
Expected probabilities of ACR response by bDMARD exposure subgroup for key comparators
| Intervention* | Probability of response, median (95% credible interval) | ||||||||
| All patients | bDMARD-naïve | bDMARD-exposed | |||||||
| ACR 20 | ACR 50 | ACR 70 | ACR 20 | ACR 50 | ACR 70 | ACR 20 | ACR 50 | ACR 70 | |
| Brodalumab 210 mg | 48.6% (37.6, 59.7) |
24.6% (16.7, 34.3) |
9.8% (16.7, 34.3) |
53.1% (40.4, 65.3) |
28.5% (18.7, 40) |
13% (18.7, 40) |
32.3% (15.9, 53.1) |
14.7% (5.6, 30.6) |
5.4% (5.6, 30.6) |
| Ixekizumab 80 mg every two weeks | 56% (44.5, 66.6) |
30.9% (21.5, 41.3) |
13.4% (21.5, 41.3) |
60.2% (45.1, 74.2) |
34.9% (22.1, 50.1) |
17.3% (22.1, 50.1) |
47.2% (28.1, 67) |
25.5% (12.1, 44.1) |
11.2% (12.1, 44.1) |
| Ixekizumab 80 mg every four weeks | 55.1% (44.5, 64.8) |
30% (21.5, 39.3) |
12.9% (21.5, 39.3) |
55.5% (43.1, 67.7) |
30.6% (20.6, 42.5) |
14.4% (20.6, 42.5) |
49.4% (29.9, 69) |
27.3% (13.2, 46.4) |
12.2% (13.2, 46.4) |
| Secukinumab 150 mg | 51.5% (42.7, 60.4) |
27% (20.2, 35) |
11.1% (20.2, 35) |
54.2% (45.4, 63.3) † |
29.4% (22.2, 38) † |
13.6% (22.2, 38) † |
40.7% (23.7, 59.7) † |
20.5% (9.6, 36.6) † |
8.3% (9.6, 36.6) † |
| Secukinumab 300 mg | 56.3% (47.4, 64.8) |
31.2% (23.7, 39.4) |
13.6% (23.7, 39.4) |
57.2% (48.2, 66.3)† |
32.1% (24.4, 41.1)† |
15.4% (24.4, 41.1)† |
51% (32.2, 69.4) † |
28.6% (14.7, 46.9)† |
13.1% (14.7, 46.9)† |
| Guselkumab 100 mg every eight weeks | 51.6% (40.5, 61) |
27.1% (18.6, 35.5) |
11.1% (18.6, 35.5) |
52.6% (41, 63.4)† |
28.1% (19.1, 38.1)† |
12.8% (19.1, 38.1)† |
63% (36.2, 84.8)‡ |
39.8% (17.3, 67)‡ |
20.7% (17.3, 67)‡ |
| Tildrakizumab 100 mg every twelve weeks | 48.9% (32.9, 64.3) |
24.9% (13.7, 38.8) |
9.9% (13.7, 38.8) |
– | – | – | – | – | – |
| Ustekinumab 45 mg | 34.2% (24.6, 45.9) |
14.5% (9.1, 22.5) |
4.8% (9.1, 22.5) |
41.8% (29.7, 55.1) |
19.6% (11.9, 30.2) |
7.9% (11.9, 30.2) |
32.9% (13.6, 59) |
15.1% (4.6, 36) |
5.6% (4.6, 36) |
| Ustekinumab 90 mg | 41.6% (32, 52.7) |
19.4% (13.2, 28) |
7.1% (13.2, 28) |
46% (33.5, 59) |
22.8% (14.1, 33.8) |
9.6% (14.1, 33.8) |
31.9% (13, 57.9) |
14.5% (4.3, 34.9) |
5.3% (4.3, 34.9) |
| Adalimumab 40 mg every two weeks | 55.8% (46.5, 63.6) |
30.7% (23, 38.1) |
13.3% (23, 38.1) |
55.5% (46.3, 64.8) |
30.6% (22.9, 39.4) |
14.4% (22.9, 39.4) |
– | – | – |
| Certolizumab 200 mg every two weeks | 61.3% (47.1, 73.8) |
35.8% (23.5, 49.4) |
16.6% (23.5, 49.4) |
55.8% (41, 70.3) |
30.9% (19.1, 45.4) |
14.6% (19.1, 45.4) |
65.3% (36.4, 88.1) |
42.2% (17.5, 72.3) |
22.5% (17.5, 72.3) |
| Certolizumab 400 mg every four weeks | 52.2% (37.9, 65.7) |
27.6% (16.9, 40.3) |
11.5% (16.9, 40.3) |
||||||
| Etanercept 50 mg once weekly | 61.8% (47.2, 75.6) |
36.3% (23.6, 51.7) |
16.9% (23.6, 51.7) |
60.3% (42.8, 75.1) |
35% (20.3, 51.3) |
17.3% (20.3, 51.3) |
– | – | – |
| Etanercept 50 mg twice weekly | 64.8% (46.7, 80.4) |
39.4% (23.2, 58.1) |
19% (23.2, 58.1) |
63.3% (40.8, 80.4) |
38% (19, 58.3) |
19.5% (19, 58.3) |
– | – | – |
| Etanercept 50 mg and Methotrexate 20 mg once weekly | 63% (44.4, 79.4) |
37.5% (21.5, 56.7) |
17.7% (21.5, 56.7) |
61.6% (38.7, 79.3) |
36.2% (17.5, 56.7) |
18.2% (17.5, 56.7) |
– | – | – |
| Golimumab 50 mg | 58.4% (43.3, 73.9) |
33% (20.6, 49.6) |
14.7% (20.6, 49.6) |
55.9% (35.3, 73.3) |
30.9% (15.3, 48.9) |
14.6% (15.3, 48.9) |
– | – | – |
| Golimumab 100 mg | 57.2% (42, 72.9) |
32% (19.7, 48.3) |
14.1% (19.7, 48.3) |
55% (34.6, 72.5) |
30.1% (14.8, 48) |
14.1% (14.8, 48) |
– | – | – |
| Infliximab 5 mg/kg | 68.4% (56.7, 79.9) |
43.2% (31.5, 57.5) |
21.8% (31.5, 57.5) |
66.6% (51.6, 79.3) |
41.4% (27.2, 56.8) |
22% (27.2, 56.8) |
– | – | – |
| Infliximab 5 mg/kg and methotrexate 15 mg | 76.5% (52, 92.1) |
52.9% (27.4, 77.7) |
29.6% (27.4, 77.7) |
75.3% (45, 92.2) |
51.5% (22, 77.9) |
30.2% (22, 77.9) |
– | – | – |
| Abatacept 125 mg | 38.4% (25.7, 51.6) |
17.2% (9.6, 27.1) |
6% (9.6, 27.1) |
45.9% (29.1, 63.8) |
22.7% (11.5, 38.4) |
9.6% (11.5, 38.4) |
26.4% (12.6, 45.1) |
11.1% (4.1, 23.9) |
3.8% (4.1, 23.9) |
| Placebo | 20.7% (9.5, 37.3) |
7.1% (2.5, 16.5) |
1.9% (2.5, 16.5) |
20.9% (10.2, 36.4)† |
7.2% (2.7, 16)† |
2.2% (2.7, 16)† |
18.3% (9.6, 30.7)† |
6.8% (2.9, 13.8)† |
2% (2.9, 13.8)† |
*Key comparators include bDMARDs at doses licensed for use in PsA or PsO.
†Based on a combination of studies reporting outcomes at week 12 or 16 and week 24.
‡Based on studies reporting outcomes at week 24 only.
ACR, American College of Rheumatology; bDMARD, biological disease-modifying antirheumatic drug; PsA, psoriatic arthritis; PsO, psoriasis.